{
    "e9809838-7529-36d6-b238-618ca4cd9684": {
        "uuid": "e9809838-7529-36d6-b238-618ca4cd9684",
        "title": "Novavax Stock: Bull vs. Bear",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/e9809838-7529-36d6-b238-618ca4cd9684/novavax-stock%3A-bull-vs.-bear.html",
        "providerPublishTime": 1655028240,
        "type": "STORY"
    },
    "65ab04fc-c07f-3086-ae5c-d4918c2ed35a": {
        "uuid": "65ab04fc-c07f-3086-ae5c-d4918c2ed35a",
        "title": "5 Cutting-Edge Growth Stocks That Can Turn $200,000 Into $1 Million by 2030",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/65ab04fc-c07f-3086-ae5c-d4918c2ed35a/5-cutting-edge-growth-stocks.html",
        "providerPublishTime": 1655024760,
        "type": "STORY"
    },
    "b0efe996-7a81-34c1-abfd-92577358a034": {
        "uuid": "b0efe996-7a81-34c1-abfd-92577358a034",
        "title": "3 Stocks Down 50% or More That You Can Buy Right Now",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/b0efe996-7a81-34c1-abfd-92577358a034/3-stocks-down-50%25-or-more.html",
        "providerPublishTime": 1654941900,
        "type": "STORY"
    },
    "dbb25ee5-9b8e-362b-b723-8528634fb19a": {
        "uuid": "dbb25ee5-9b8e-362b-b723-8528634fb19a",
        "title": "Novavax Dive Continues As FDA Reviews New Covid Shot Information",
        "publisher": "Investor's Business Daily",
        "link": "https://finance.yahoo.com/m/dbb25ee5-9b8e-362b-b723-8528634fb19a/novavax-dive-continues-as-fda.html",
        "providerPublishTime": 1654891627,
        "type": "STORY"
    },
    "3bebd086-2e86-4154-894a-0384dfd1bf8e": {
        "uuid": "3bebd086-2e86-4154-894a-0384dfd1bf8e",
        "title": "Changes to Novavax manufacturing data were minor and process related: Source",
        "publisher": "Yahoo Finance",
        "link": "https://finance.yahoo.com/news/changes-to-novavax-manufacturing-data-were-minor-and-process-related-214254990.html",
        "providerPublishTime": 1654810974,
        "type": "STORY"
    },
    "f161f9f9-a75a-3c28-8d86-96b93025c44a": {
        "uuid": "f161f9f9-a75a-3c28-8d86-96b93025c44a",
        "title": "Why Novavax Stock Plummeted on Thursday",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/f161f9f9-a75a-3c28-8d86-96b93025c44a/why-novavax-stock-plummeted.html",
        "providerPublishTime": 1654806832,
        "type": "STORY"
    },
    "50860945-aca3-31a8-901d-53a231e73ef9": {
        "uuid": "50860945-aca3-31a8-901d-53a231e73ef9",
        "title": "Novavax CEO Stanley Erck: 'Everything is on track' for Covid vaccine",
        "publisher": "American City Business Journals",
        "link": "https://finance.yahoo.com/m/50860945-aca3-31a8-901d-53a231e73ef9/novavax-ceo-stanley-erck%3A.html",
        "providerPublishTime": 1654797242,
        "type": "STORY"
    },
    "82a18f58-a97c-336b-a6bd-d6ab61d86963": {
        "uuid": "82a18f58-a97c-336b-a6bd-d6ab61d86963",
        "title": "The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-bristol-144302383.html",
        "providerPublishTime": 1654785782,
        "type": "STORY"
    }
}